Fig. 6.

OPN drives fibrogenic protein synthesis via activation of the CD44/P-FAK/P-AKT cascade. A, B A549 cells were treated with OPN (1 μg/ml) or not, and harvested CO-IP test and western blot after 48 h. A Identification of CD44 from CCL1 immunoprecipitates in alveolar epithelial cells by MS analysis. B Immunoblots of CD44, P-FAK, FAK, P-AKT, AKT, Snail1 of A549 cells. C A549 cells were transfected with LV-negative control (NC) or LV-CD44-siRNA and then treated with OPN (1 μg/ml) for 72 h. Immunoblots of P-FAK, FAK, P-AKT, AKT, CD44, Snail1, N-CAD and E-CAD of A549 cells. D A549 cells were pretreated with defactinib and treated with OPN 1 h later for 48 h. Immunoblots of Collagen I, P-FAK, FAK, P-AKT, AKT, Vimentin, α-SMA, N-CAD and E-CAD of A549 cells. D, E PCLS were obtained from control mice and mice with pulmonary fibrosis and treated with P-FAK inhibitor. E Immunoblots of Collagen I, P-FAK, P-AKT, AKT, α-SMA of PCLS. F Confocal microscopy showed α-SMA (green), and DNA dye DAPI (cyan) in bleomycin PCLS treated P-FAK inhibitor with and matched group, showing fibrogenic protein synthesis